Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus chemotherapy versus cetuximab plus chemotherapy in first-line wild-type left-sided metastatic colorectal cancer
NL-OMON60565Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab and cetuximab in colorectal cancer (CRC), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Feb 2025; status: recruiting.
02
Drugs
amivantamabcetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON60565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60565.